YAP1 and eye disorder: However, disruption of YAP1 signaling in the nucleus can be achieved by the porphyrin compound verteporfin, which is a photosensitizer used to treat excess vascularization in eye disease and has been found to bind to YAP1 and change its conformation to inhibit the YAP1/TEAD interaction (Figure 6) 18, 37.